ClinicaliQ Trial Snapshot
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) — Recruiting • Phase III • Diabetes / Metabolic • NCT07684144.
- What is being tested: Long-term efficacy, safety, and tolerability of maridebart cafraglutide, a novel dual-action GLP-1/GIP receptor agonist, in patients with concurrent obesity and type 2 diabetes mellitus through an extension phase of an ongoing clinical trial.
- Patient eligibility overview: Participants are individuals who have previously completed the parent trial (MARITIME-2, NCT06858878) and have established diagnoses of both type 2 diabetes mellitus and obesity, ensuring evaluation in a population with significant metabolic comorbidity.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Eligibility Snapshot
- : * Signed informed consent form (ICF) indicating compliance with the requirements and restrictions listed in the ICF and this protocol. * Participants completing Study 20210184 must meet the following criteria: * Completed the Week 72 visit in Study 20210184. * Did not permanently discontinue the investigational product in the parent trial (20210184). * Randomized within 7 days of week 72 visit in the parent trial. * Participants must use protocol-specified contraception during treatment and for 16 weeks after the last dose of trial intervention.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.